GlaxoSmithKline and Corixa Sign on as National Sponsors of The Leukemia & Lymphoma Society's Light The Night Walk
September 21 2004 - 9:15AM
PR Newswire (US)
GlaxoSmithKline and Corixa Sign on as National Sponsors of The
Leukemia & Lymphoma Society's Light The Night Walk WHITE
PLAINS, N.Y., Sept. 21 /PRNewswire/ -- Pharmaceutical companies
GlaxoSmithKline and Corixa Corporation have signed on as national
sponsors of The Leukemia & Lymphoma Society's Light The Night
Walk. The companies will provide support to help the Society
advance its mission: to cure leukemia, lymphoma, Hodgkin's disease
and myeloma and improve the quality of life of patients and their
families. "We're thrilled to have GlaxoSmithKline and Corixa as
national sponsors of this year's Light The Night Walk," said Dwayne
Howell, President and C.E.O. of The Leukemia & Lymphoma
Society. "We appreciate their generosity and are grateful for their
commitment to help make this year's event the best yet." Light The
Night is the Society's annual fall campaign held in hundreds of
communities around the country to raise money for blood cancer
research and patient services. Teams of co-workers, families and
friends walk together in twilight holding illuminated balloons --
white for survivors and red for supporters. The walk commemorates
lives touched by cancer. Last year, the walk raised more than $18
million. This year's goal is $23 million. "As important therapeutic
advances are made against non-Hodgkin's lymphoma and other
blood-borne cancers, the role that The Leukemia & Lymphoma
Society plays in educating and informing patients and their
caregivers about their disease and its treatment is absolutely
critical," said Steven Gillis, PhD, Chairman and CEO of Corixa
Corporation. "The dedicated employees of Corixa Corporation and
GlaxoSmithKline are pleased to join the unwavering efforts of the
thousands of Light The Night volunteers around the country in this
important event." "GlaxoSmithKline, together with Corixa
Corporation, is proud to sponsor The Leukemia & Lymphoma
Society's important annual fundraising event," said Kevin Lokay,
Vice President, GlaxoSmithKline Oncology. "The Light The Night
Walks held in communities around the country help to raise
awareness of blood- borne cancers, such as lymphoma, and to provide
invaluable information and services to patients." Corixa and
GlaxoSmithKline co-market the anti-cancer radioimmunotherapy Bexxar
(Tositumomab and Iodine I 131 Tositumomab) in the United States.
Radioimmunotherapy represents a novel approach to the treatment of
non- Hodgkin's lymphoma. For more information, call the Society's
Information Resource Center at (800) 955-4572. Register for Light
The Night Today Registering for a Light The Night Walk event in
your community is easy. Call (877) LTN-WALK or visit
http://www.lightthenight.org/. About Corixa Corixa (NASDAQ:CRXA) is
a developer of immunotherapeutics with a commitment to treating and
preventing cancer and infectious diseases by understanding and
directing the immune system. On June 30, 2003, Corixa announced
that the FDA approved the BEXXAR(R) therapeutic regimen
(Tositumomab and Iodine I 131 Tositumomab) for the treatment of
patients with CD20 positive, follicular NHL, with and without
transformation, whose disease is refractory to Rituximab and has
relapsed following chemotherapy. Corixa is focused on
immunotherapeutic products and has a broad technology platform
enabling both fully integrated vaccine design and the use of its
separate, proprietary product components on a standalone basis. In
addition to BEXXAR, Corixa currently has multiple programs in
clinical development, including several product candidates that
have advanced to and through late stage clinical trials. The
company partners with numerous developers and marketers of
pharmaceuticals, targeting products that are Powered by Corixa(TM)
technology with the goal of making its potential products available
to patients around the world. Corixa was founded in 1994 and is
headquartered in Seattle, with additional operations in Hamilton,
Mont., and South San Francisco. For more information, please visit
Corixa's Web site at http://www.corixa.com/. About GlaxoSmithKline
GlaxoSmithKline (NYSE:GSK) is one of the world's leading
research-based pharmaceutical and healthcare companies.
GlaxoSmithKline is committed to improving the quality of human life
by enabling cancer patients to do more, feel better and live
longer. For more information, visit http://www.gsk.com/. About The
Leukemia & Lymphoma Society The Leukemia & Lymphoma
Society(R), headquartered in White Plains, NY, is the world's
largest voluntary health organization dedicated to funding blood
cancer research and providing education and patient services. The
Society's mission is to cure leukemia, lymphoma, Hodgkin's disease
and myeloma, and to improve the quality of life of patients and
their families. Since its founding in 1949, the Society has
invested more than $360 million in research specifically targeting
leukemia, lymphoma and myeloma. Last year alone, the Society made
more than 812,000 contacts with patients, caregivers and healthcare
professionals through services provided at its home office and by
its 63 chapters nationwide. For more information, visit
http://www.lls.org/. Contacts: Jon Garbo, The Leukemia &
Lymphoma Society, (914) 821-8969 Jim DeNike, Corixa Corporation,
(206) 754-5716 Danielle Halstrom, GlaxoSmithKline, (215) 751-3981
Kristin Paulina, Sam Brown Communications, (610) 524-2959
DATASOURCE: The Leukemia & Lymphoma Society CONTACT: Jon Garbo,
The Leukemia & Lymphoma Society, +1-914-821-8969; Jim DeNike,
Corixa Corporation, +1-206-754-5716; Danielle Halstrom,
GlaxoSmithKline, +1-215-751-3981; Kristin Paulina, Sam Brown
Communications, +1-610-524-2959 Web site:
http://www.lightthenight.org/ http://www.corixa.com/
http://www.gsk.com/ http://www.lls.org/
Copyright
Corixa (NASDAQ:CRXA)
Historical Stock Chart
From May 2024 to Jun 2024
Corixa (NASDAQ:CRXA)
Historical Stock Chart
From Jun 2023 to Jun 2024